Objective:

To discuss the transition from batch to continuous manufacturing in the pharmaceutical industry, highlighting recent FDA approvals and industry trends.

Approach:

• FDA Approval: The FDA approved Janssen to switch from batch to continuous manufacturing for the production of Prezista (darunavir).
• Industry Guidance: The FDA released draft guidance in 2015 to assist pharmaceutical manufacturers in implementing new technologies.
• Historical Context: Lawrence Yu from the FDA noted that pharmaceutical production processes have seen little change over the past 50 years.
• Current Adoption: Manufacturers like Vertex Pharmaceuticals have adopted continuous manufacturing for new products, while Janssen is the first to do so for an already approved drug.
• Future Plans: Janssen plans to transition several products to continuous manufacturing and has expanded collaboration with Rutgers School of Engineering.
• Industry Trends: Other companies, such as GlaxoSmithKline, are also investing in continuous manufacturing facilities.

Key Findings:

• Janssen is the first company to switch an already approved drug to continuous manufacturing.
• Continuous manufacturing offers faster production and more reliable products.
• The FDA encourages the pharmaceutical industry to consider transitioning to continuous manufacturing.

Interpretation:

Limitations:

• Transitioning from batch to continuous manufacturing is complex and challenging for drug manufacturers.

Conclusion:

Sources:

• FDA Blog Post